Abstract: The present disclosure relates to compositions and methods for targeting antigenically variable pathogens and diseases. Embodiments of the present disclosure involve of the construction of variable epitope libraries (VELs) containing mutated versions of epitopes derived from antigens associated with various diseases for treating subjects in both therapeutic and prophylactic settings. The present disclosure also provides compositions and methods for the production of VELs based on CTL-derived epitopes of survivin, an oncogenic inhibitor-of-apoptosis. Given the large number of potential epitopes expressed in tumors, and the dynamic nature of the tumor epitope landscape, there is a need to develop compositions and methods for targeting various antigenic epitopes to counteract immune escape.

Abstract: The present disclosure relates to compositions and methods for targeting antigenically variable pathogens and diseases. Embodiments of the present disclosure involve of the construction of variable epitope libraries (VELs) containing mutated versions of epitopes derived from antigens associated with various diseases for treating subjects in both therapeutic and prophylactic settings. The present disclosure also provides compositions and methods for the production of VELs based on CTL-derived epitopes of survivin, an oncogenic inhibitor-of-apoptosis. Given the large number of potential epitopes expressed in tumors, and the dynamic nature of the tumor epitope landscape, there is a need to develop compositions and methods for targeting various antigenic epitopes to counteract immune escape.

Abstract: Described herein is the application of Variable Epitope Libraries (VELs) as immunogens for the generation of vaccines against a novel coronavirus, named SARS-CoV-2. The VELs bearing combinatorial epitope libraries target antigenic variability of viruses such as SARS-CoV-2, and cancer, thus representing a true alternative to traditional vaccine platforms.

Abstract: The present invention refers to the use of the peptide defined by the amino acid sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A, named GK-1, to be used as an antitumor and antimetastatic agent or for the treatment of cancer, specifically of basal cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, and preferably for the treatment of breast cancer.

Abstract: The present invention refers to the use of the peptide defined by the amino acid sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A, named GK-1, to be used as an antitumor and antimetastatic agent or for the treatment of cancer, specifically of basal cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma, and preferably for the treatment of breast cancer.

Abstract: The present disclosure relates to compositions and methods for targeting antigenically variable pathogens and diseases. Embodiments of the present disclosure involve of the construction of variable epitope libraries (VELs) containing mutated versions of epitopes derived from antigens associated with various diseases for treating subjects in both therapeutic and prophylactic settings. The present disclosure also provides compositions and methods for the production of VELs based on CTL-derived epitopes of survivin, an oncogenic inhibitor-of-apoptosis. Given the large number of potential epitopes expressed in tumors, and the dynamic nature of the tumor epitope landscape, there is a need to develop compositions and methods for targeting various antigenic epitopes to counteract immune escape.

Abstract: Specifically, methods for patient stratification and selection of personalized peptide based treatments and vaccines are disclosed, including assays for identifying antigenic and immunogenic peptides involved in immune responses of mammals against pathogens, cancer and other diseases by interrogating the T lymphocyte repertoire of a patient using combinatorial T-cell epitope and mimotope libraries.

Abstract: The present disclosure relates to compositions and methods for targeting antigenically variable pathogens and diseases. Embodiments of the present disclosure involve of the construction of variable epitope libraries (VELs) containing mutated versions of epitopes derived from antigens associated with various diseases for treating subjects in both therapeutic and prophylactic settings. The present disclosure also provides compositions and methods for the production of VELs based on CTL-derived epitopes of survivin, an oncogenic inhibitor-of-apoptosis. Given the large number of potential epitopes expressed in tumors, and the dynamic nature of the tumor epitope landscape, there is a need to develop compositions and methods for targeting various antigenic epitopes to counteract immune escape.

Abstract: The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A (SEQ ID No. 1) and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchioalveolar lavages.

Abstract: The present disclosure relates to compositions and methods for targeting antigenically variable pathogens and diseases. Embodiments of the present disclosure involve of the construction of variable epitope libraries (VELs) containing mutated versions of epitopes derived from antigens associated with various diseases for treating subjects in both therapeutic and prophylactic settings. The present disclosure also provides compositions and methods for the production of VELs based on CTL-derived epitopes of survivin, an oncogenic inhibitor-of-apoptosis. Given the large number of potential epitopes expressed in tumors, and the dynamic nature of the tumor epitope landscape, there is a need to develop compositions and methods for targeting various antigenic epitopes to counteract immune escape.

Abstract: The present invention is directed to the use of FGK-1 immunopotentiator, composed by the peptide named GK-1, characterized by the sequence G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A and linked to the pVIII surface protein of M13 filamentous phage, to prepare pharmaceutical products potentiating the protective immune response of vaccine antigens when used by itself or conjointly with these antigens administered either intranasally, subcutaneously, or intramuscularly, yielding an increase in the level of specific antibodies against vaccine antigens in serum and in bronchoalveolar lavages.

Abstract: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (A?) protein or peptide. Anti-A? antibodies are selected and sequenced. In certain embodiments, synthetic A? binding peptides are designed and prepared, using portions of the anti-A? antibody sequences. The antibodies and peptides are of use for treatment of AD or for treatment of individuals at risk of developing AD. Compositions comprising anti-A? antibodies or A? binding peptides are also disclosed.

Abstract: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (A?) protein or peptide. Anti-A? antibodies are selected and sequenced. In certain embodiments, synthetic A? binding peptides are designed and prepared, using portions of the anti-A? antibody sequences. The antibodies and peptides are of use for treatment of AD or for treatment of individuals at risk of developing AD. Compositions comprising anti-A? antibodies or A? binding peptides are also disclosed.

Abstract: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (A?) protein or peptide. Anti-A? antibodies are selected and sequenced. In certain embodiments, synthetic A? binding peptides are designed and prepared, using portions of the anti-A? antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-A? antibodies or A? binding peptides are also disclosed.

Abstract: The present invention provides compositions and methods for the therapeutic and/or prophylactic treatment of pathogen infections and/or disease states. The compositions may comprise variable epitope libraries (VELs), containing antigenic epitopes with one or more amino acid substitutions in the native epitope sequence. In preferred embodiments, the substituted amino acid may be replaced with each of the 19 other naturally occurring amino acids. In more preferred embodiments, multiple amino acid residues may be substituted. Such compositions and methods may be of use for production of vaccines against pathogens or diseases that show a high degree of genetic variability.

Abstract: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (A?) protein or peptide. Anti-A? antibodies are selected and sequenced. In certain embodiments, synthetic A? binding peptides are designed and prepared, using portions of the anti-A? antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-A? antibodies or A? binding peptides are also disclosed.

Abstract: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (A?) protein or peptide. Anti-A? antibodies are selected and sequenced. In certain embodiments, synthetic A? binding peptides are designed and prepared, using portions of the anti-A? antibody sequences. The antibodies and peptides are of use for treatment of AD or for treatment of individuals at risk of developing AD. Compositions comprising anti-A? antibodies or A? binding peptides are also disclosed.